Lab
Gentox Lab Services LLC
Gentox Lab Services LLC was paid $107K by Medicaid between Jan 2018 and Jan 2022, across 59 billing codes. Its largest line is 80346, — 13% of everything it billed.
33Billing provider infoGENTOX LAB SERVICES LLC
FARMERS BRANCH, TX 75244
FARMERS BRANCH, TX 75244
33aNPI1336593888assigned 04/21/2016
33bProvider typeClinical Medical Laboratory
28Total paid$107K
24GClaims11,172
24DCodes billed59
24AFirst – last monthJan 2018 – Jan 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#147 of 436
Median peer was paid$17K
This provider vs. median6.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,708 | $98K | |
| 2019 | 68 | $0.00 | |
| 2020 | 53 | $0.00 | |
| 2022 | 343 | $9K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80346 | 13% | 302 | 212 | $14K | |
| 80361 | 11% | 290 | 201 | $12K | |
| 80337 | 9.0% | 288 | 200 | $10K | |
| 80364 | 6.3% | 300 | 211 | $7K | |
| 80324 | 6.2% | 288 | 200 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.6% | 115 | 92 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.7% | 295 | 235 | $5K |
| 80369 | 2.9% | 290 | 201 | $3K | |
| 80332 | 2.9% | 288 | 200 | $3K | |
| 80345 | 2.9% | 297 | 212 | $3K | |
| 80321 | 1.9% | 275 | 196 | $2K | |
| 80376 | 1.8% | 285 | 200 | $2K |
47 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.8% | 114 | $2K |
| 80372 | 1.8% | 301 | $2K | |
| 80365 | 1.8% | 301 | $2K | |
| 80373 | 1.8% | 301 | $2K | |
| 80367 | 1.8% | 289 | $2K | |
| 80360 | 1.8% | 289 | $2K | |
| 80368 | 1.8% | 290 | $2K | |
| 80358 | 1.8% | 301 | $2K | |
| 80348 | 1.8% | 301 | $2K | |
| 80354 | 1.8% | 301 | $2K | |
| 80366 | 1.8% | 297 | $2K | |
| 80357 | 1.8% | 298 | $2K | |
| 80353 | 1.8% | 291 | $2K | |
| 80338 | 1.8% | 288 | $2K | |
| 80323 | 1.8% | 291 | $2K | |
| 80355 | 1.7% | 299 | $2K | |
| 83992 | 1.1% | 293 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 114 | $787.15 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 84 | $766.27 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 34 | $386.37 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19 | $116.72 |
| 80053 | Comprehensive metabolic panel | <1% | 365 | $13.51 |
| 80061 | Lipid panel | <1% | 354 | $13.13 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 360 | $12.60 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 291 | $4.55 |
| 84439 | 0% | 145 | $0.00 | |
| 84481 | 0% | 43 | $0.00 | |
| 84450 | 0% | 26 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 95 | $0.00 |
| 85610 | 0% | 34 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 59 | $0.00 |
| 81408 | 0% | 14 | $0.00 | |
| 83540 | 0% | 26 | $0.00 | |
| 84550 | 0% | 22 | $0.00 | |
| 84403 | 0% | 12 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 14 | $0.00 |
| 99000 | 0% | 102 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 246 | $0.00 |
| 84153 | 0% | 40 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 253 | $0.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 38 | $0.00 |
| 80050 | General health panel | 0% | 41 | $0.00 |
| 81001 | 0% | 94 | $0.00 | |
| 82607 | 0% | 32 | $0.00 | |
| 83735 | 0% | 30 | $0.00 | |
| 82746 | 0% | 14 | $0.00 | |
| 82043 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIONI, FRED (OWNER)